Ibalizumab Shortage: What Providers and Prescribers Need to Know in 2026

Clinical Context: Why Ibalizumab Access Is a High-Stakes Issue

Ibalizumab (Trogarzo) is FDA-approved for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multidrug-resistant (MDR) HIV-1 who are failing their current antiretroviral regimen. As of 2026, it remains one of only three novel antiretrovirals approved specifically for this population—alongside fostemsavir (Rukobia) and lenacapavir (Sunlenca).

For HTE patients, losing access to ibalizumab—even briefly—can have serious clinical consequences. Missed doses allow viral rebound and may contribute to further resistance development. Unlike most oral antiretrovirals, ibalizumab has a mandatory re-loading protocol: if a maintenance dose is delayed 3 or more days beyond the scheduled date, a 2,000 mg loading dose must be re-administered before resuming the 800 mg q2w maintenance schedule.

Current Access Landscape in 2026

Ibalizumab is not on the FDA's official drug shortage list as of 2026. However, access difficulties are widespread and stem from several structural factors:

Specialty-only distribution: Ibalizumab is dispensed exclusively through specialty pharmacies and administered by IV infusion (diluted 250 mL 0.9% NaCl IV infusion or IV push) at a clinical facility or via home infusion service.

Payer prior authorization: Cigna, UnitedHealthcare, Molina, and most other commercial payers require PA. PA criteria generally include: documented MDR HIV-1 with resistance to 3+ ARV classes, current regimen failure, and prescription of an optimized background regimen (OBR) containing at least one fully active agent.

Medicare Part B billing: As a provider-administered infusion, ibalizumab is billed under Medicare Part B (HCPCS: J1746—ibalizumab-uiyk, 10 mg), not Part D. Beneficiary cost sharing may be up to 20% with no cap unless supplemental coverage applies.

High list price: Approximately $9,000/month without insurance, making self-pay access practically impossible.

Prior Authorization: Optimizing Your PA Submission

A well-prepared PA submission significantly reduces the risk of denial and the time to approval. Key elements to include:

Documentation of MDR HIV-1: genotypic and phenotypic resistance test results showing resistance to 3+ ARV classes

Current viral load and CD4+ T cell count with dates

Complete antiretroviral treatment history—including all prior regimens, reasons for discontinuation, and demonstrated virologic failure

Description of the planned optimized background regimen (OBR) to be used alongside ibalizumab

Letter of medical necessity explicitly referencing the TMB-301 Phase 3 trial data and FDA approval

Handling PA Denials and Appeals

Initial PA denials are common but often reversible with a robust appeal. Recommended approach:

Request peer-to-peer review with the plan's medical director—this is often the fastest path to overturning a denial.

File a formal written appeal with supporting clinical documentation and published guidelines (DHHS HIV Treatment Guidelines).

Engage Thera Patient Support (1-833-238-4372) for appeal support and access to a bridge supply while the appeal is pending.

Financial Assistance Programs for Patients

Key programs to communicate to patients:

Thera Patient Support Co-Pay Program: Commercially insured patients may pay as little as $0 per injection. Call 1-833-238-4372 or visit trogarzo.com.

AIDS Drug Assistance Programs (ADAPs): Federal and state ADAPs can cover ibalizumab for uninsured or underinsured patients. Thera Patient Support can assist with ADAP enrollment.

Manufacturer Patient Assistance Program (PAP): For patients who do not qualify for or cannot obtain insurance coverage, direct application through Thera Patient Support may provide access at reduced or no cost.

Considerations for Switching to an Alternative

When ibalizumab access is protracted, consider whether fostemsavir (Rukobia) or lenacapavir (Sunlenca) may be viable alternatives:

Fostemsavir (Rukobia): 600 mg oral tablet BID; attachment inhibitor; no cross-resistance with ibalizumab; has drug interactions via CYP3A.

Lenacapavir (Sunlenca): SQ injection every 6 months; capsid inhibitor; may be more cost-effective over a patient's lifetime per recent cost-utility analyses.

Notably, ibalizumab and lenacapavir have been used in combination in some heavily treatment-experienced patients with very limited options, with published case series demonstrating tolerability and viral load reduction.

How medfinder Can Help Your Patients

For patients navigating access barriers to ibalizumab, medfinder is a concierge service that calls pharmacies and infusion providers near a patient's location to identify who can fill their prescription—cutting out hours of phone calls and reducing time to treatment. Providers can recommend medfinder.com to their patients as a resource for all medications, not just ibalizumab.